iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference
Insight Molecular Diagnostics (Nasdaq: IMDX) has scheduled its second quarter 2025 financial results release for August 11, 2025, after market close. The company will host a live Zoom webinar at 2:00 PM PT / 5:00 PM ET on the same day to discuss the results, followed by a Q&A session.
Additionally, CEO Josh Riggs and CFO Andrea James will participate in the 10th Annual Needham Virtual MedTech & Diagnostics Conference on August 12, 2025, where they will be available for one-on-one meetings with investors.
Insight Molecular Diagnostics (Nasdaq: IMDX) ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per il 11 agosto 2025, dopo la chiusura del mercato. La società terrà un webinar live su Zoom alle 14:00 PT / 17:00 ET lo stesso giorno per discutere i risultati, seguito da una sessione di domande e risposte.
Inoltre, il CEO Josh Riggs e il CFO Andrea James parteciperanno alla 10ª Conferenza Annuale Virtuale Needham MedTech & Diagnostics il 12 agosto 2025, dove saranno disponibili per incontri individuali con gli investitori.
Insight Molecular Diagnostics (Nasdaq: IMDX) ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el 11 de agosto de 2025, después del cierre del mercado. La compañía realizará un seminario web en vivo por Zoom a las 2:00 PM PT / 5:00 PM ET ese mismo día para discutir los resultados, seguido de una sesión de preguntas y respuestas.
Además, el CEO Josh Riggs y la CFO Andrea James participarán en la 10ª Conferencia Anual Virtual Needham MedTech & Diagnostics el 12 de agosto de 2025, donde estarán disponibles para reuniones individuales con inversores.
Insight Molecular Diagnostics (나스닥: IMDX)는 2025년 2분기 재무 결과를 2025년 8월 11일 시장 마감 후에 발표할 예정입니다. 회사는 같은 날 오후 2시 PT / 오후 5시 ET에 Zoom 라이브 웨비나를 개최하여 결과를 논의하고, 이어서 질의응답 시간을 가질 예정입니다.
또한 CEO Josh Riggs와 CFO Andrea James는 2025년 8월 12일에 열리는 제10회 연례 니드햄 가상 MedTech & Diagnostics 컨퍼런스에 참여하여 투자자들과 일대일 미팅을 진행할 예정입니다.
Insight Molecular Diagnostics (Nasdaq : IMDX) a prévu de publier ses résultats financiers du deuxième trimestre 2025 le 11 août 2025 après la clôture du marché. La société organisera un webinaire en direct sur Zoom à 14h00 PT / 17h00 ET le même jour pour discuter des résultats, suivi d'une séance de questions-réponses.
De plus, le PDG Josh Riggs et la directrice financière Andrea James participeront à la 10e conférence annuelle virtuelle Needham MedTech & Diagnostics le 12 août 2025, où ils seront disponibles pour des rencontres individuelles avec les investisseurs.
Insight Molecular Diagnostics (Nasdaq: IMDX) hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 11. August 2025 nach Börsenschluss geplant. Das Unternehmen wird am selben Tag um 14:00 Uhr PT / 17:00 Uhr ET ein Live-Zoom-Webinar abhalten, um die Ergebnisse zu besprechen, gefolgt von einer Fragerunde.
Außerdem werden CEO Josh Riggs und CFO Andrea James an der 10. jährlichen Needham Virtual MedTech & Diagnostics Conference am 12. August 2025 teilnehmen, wo sie für Einzelgespräche mit Investoren zur Verfügung stehen.
- None.
- None.
NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q2 2025 Earnings Webinar.
An archived replay will be available after the call concludes on iMDX’s investor relations website at https://investors.imdxinc.com/.
10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Separately, on August 12th, Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 10th Annual Needham Virtual MedTech & Diagnostics Conference, taking place from August 11-12, 2025.
Investors wishing to book one-on-one meetings with management are encouraged to reach out to their Needham sales representative.
Event: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Dates: August 12, 2025
Location: Virtual
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.
iMDx™, GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, and VitaGraft™ are trademarks of Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025. The company’s new NASDAQ symbol became effective June 18. Investors may visit https://investors.imdxinc.com/ for more information.
Investor Contact:
Doug Farrell
LifeSci Advisors LLC
dfarrell@lifesciadvisors.com
FAQ
When will IMDX release its Q2 2025 earnings?
How can investors access IMDX's Q2 2025 earnings call?
Who will represent IMDX at the Needham Virtual MedTech Conference?
How can investors schedule meetings with IMDX management at the Needham Conference?
